FDA Approves Automated Insulin Delivery and Monitoring Syste
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
U.S. Food and Drug Administration approved the MiniMed 770G System, a hybrid closed-loop diabetes management device.

The 770G System is a first-of-a-kind device for patients aged 2 to 6 years. It is the first legally marketed device that can automatically adjust insulin delivery based on continuous glucose monitor values for this patient population.

The system works by measuring glucose levels in the body every five minutes and automatically adjusting insulin delivery by either administering or withholding insulin.

Includes a sensor that attaches to the body to measure glucose levels under the skin; an insulin pump strapped to the body; and an infusion patch connected to the pump with a catheter that delivers insulin.

While the device automatically adjusts insulin levels, users need to manually request insulin doses to counter carbohydrate consumption at mealtime.

Risks: hypoglycemia, hyperglycemia, as well as skin irritation or redness around the device’s infusion patch.

This device is not approved for use in children younger than 2 years old and in individuals who require less than eight units of insulin per day.

The approval of the MiniMed 770G hybrid closed loop system was granted to Medtronic.

Source:https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-automated-insulin-delivery-and-monitoring-system-use-young-pediatric
Dr. T●●●●z H●●●●●●i and 2 other likes this2 shares
Like
Comment
Share